ELI LILLY & Co is 103.2x more valuable than ARROWHEAD PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $10.37 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARWR | LLY |
|---|---|---|
| Market cap | $10.37 B | $1.070 T |
| US-listed rank | #921 | #10 |
| Revenue (latest FY) | $829.45M | $65.18B |
| Net income (latest FY) | -$1.63M | $20.64B |
| Net margin | -0.2% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 1,347 | 989 |
ELI LILLY & Co is 103.2x more valuable than ARROWHEAD PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $10.37 B).
In their latest fiscal years, ARROWHEAD PHARMACEUTICALS, INC. reported $829.45M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: ARROWHEAD PHARMACEUTICALS, INC. and ELI LILLY & Co, or browse the full rankings.